Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Sigall KassuttoEric S Rosenberg

Abstract

Treatment of acute human immunodeficiency virus type 1 (HIV-1) infection may have unique immunologic, virological, and clinical benefits. However, the timing of treatment, optimal starting regimens, and expected response to therapy have not been defined.Methods. One hundred two subjects treated during acute and early HIV-1 infection were observed prospectively to determine the effect of time elapsed before initiation of therapy on time to virological suppression and absolute CD4+ cell count. Subjects were divided into pre- and postseroconversion groups on the basis of HIV-1 antibody status at the time of initiation of treatment. Absolute CD4+ cell counts were compared between these groups and with those of historical untreated persons who had experienced seroconversion. Potential predictors of time to virological suppression and CD4+ cell count at > or =12 months were assessed. Ninety-nine (97%) of 102 subjects achieved virological suppression. The median time to suppression was 11.1 weeks (95% confidence interval, 9.4-14.9) and was independent of initial regimen. The mean CD4+ cell count at 12 months was 702 cells/mm3 (95% confidence interval, 654-750 cells/mm3) and showed an increasing trend over 60 months. Treated subjects d...Continue Reading

Associated Clinical Trials

References

Dec 1, 1993·American Journal of Epidemiology·L P JacobsonL K Schrager
Jul 11, 1998·JAMA : the Journal of the American Medical Association·R S JanssenM P Busch
Jan 27, 2000·JAMA : the Journal of the American Medical Association·C C CarpenterP A Volberding
Mar 29, 2000·Proceedings of the National Academy of Sciences of the United States of America·A OxeniusR E Phillips
Jun 3, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S Low-BeerJ S Montaner
Oct 12, 2000·Nature·E S RosenbergB D Walker
Oct 12, 2001·JAMA : the Journal of the American Medical Association·C D PilcherL Perrin
Jan 31, 2002·Annual Review of Medicine·Rajesh T Gandhi, Bruce D Walker
Sep 11, 2002·Antiviral Research·Peter BorowskiHerbert Schmitz
Dec 12, 2003·The New England Journal of Medicine·Gregory K RobbinsUNKNOWN AIDS Clinical Trials Group 384 Team
May 4, 2004·The Journal of Infectious Diseases·Christopher D PilcherUNKNOWN Duke-UNC-Emory Acute HIV Consortium
Jul 14, 2004·JAMA : the Journal of the American Medical Association·Joel E GallantUNKNOWN 903 Study Group
Nov 5, 2004·PLoS Medicine·Daniel E KaufmannBruce D Walker
Apr 6, 2005·The Journal of Infectious Diseases·Maria J WawerThomas C Quinn
Apr 6, 2005·The Journal of Infectious Diseases·Matthew C StrainJoseph K Wong

❮ Previous
Next ❯

Citations

Jan 11, 2007·Bulletin of Mathematical Biology·B M AdamsE S Rosenberg
Oct 6, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Lena Al-HarthiAlan Landay
Jan 1, 2008·Journal of Biological Dynamics·H T BanksE S Rosenberg
Apr 10, 2010·AIDS Research and Human Retroviruses·Radjin SteingroverJan M Prins
Feb 24, 2012·The Journal of Infectious Diseases·Man CharuratWilliam Blattner
Dec 20, 2007·AIDS·Kimberly A PowersUNKNOWN Malawi UNC Project Acute HIV Study Team
Feb 6, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Linda G ApuzzoJoseph B Margolick
May 28, 2010·Journal of Virology·Toshiyuki MiuraBruce D Walker
Apr 16, 2011·Journal of Neurovirology·Margaret R LentzR G González
Mar 22, 2012·AIDS and Behavior·Roger C McIntosh, Monica Rosselli
Oct 29, 2013·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Apr 24, 2010·Emergency Medicine Clinics of North America·Wesley H Self
May 16, 2007·Infectious Disease Clinics of North America·Nicola M Zetola, Christopher D Pilcher
May 1, 2012·Immunopharmacology and Immunotoxicology·Bartholomew Okechukwu Ibeh, Ijeoma Kalu Emeka-Nwabunnia
Apr 14, 2011·AIDS·Cynthia L GayUNKNOWN Duke-UNC Acute HIV Infection Consortium
Jan 1, 2008·Current Opinion in HIV and AIDS·Cristina CelleraiSabine Kinloch-de Loes
Oct 11, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Remonie SengUNKNOWN ANRS PRIMO and SEROCO Study Groups
Mar 18, 2006·International Journal of Epidemiology·Maarten F Schim van der LoeffHilton C Whittle
Mar 7, 2007·Current HIV/AIDS Reports·Satya Dandekar
Jan 20, 2012·Current Opinion in HIV and AIDS·Vladimir Novitsky, Max Essex
May 11, 2016·AIDS·Trevor A CrowellUNKNOWN RV254SEARCH010 Study Group
Jul 12, 2017·Journal of the International AIDS Society·Sarah E RutsteinJoseph D Tucker
Jul 12, 2017·Journal of the International AIDS Society·Jintanat AnanworanichMerlin L Robb
Aug 14, 2021·PLoS Pathogens·Michael J CorleyUNKNOWN SEARCH010/RV254 and SEARCH013/RV304 study groups
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.